Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Atherley

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Eye (London, England)|March 5, 2005
Deep sclerectomy augmented with mitomycin CN Anand, C Atherley
Eye (London, England)|September 25, 2004
Influence of ethnic origin on the incidence of keratoconus and associated atopic disease in Asian and white patientsI Cozma, C Atherley, N J James
Diabetes, Obesity & Metabolism|June 18, 2026
One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin-Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin-Requiring Type 2 DiabetesNinoschka C D'Souza, Emily G Hoffman, Sara C Atherley, et al.
Endocrinology|January 8, 2026
Prolonged somatostatin receptor 2 antagonism enhances glucagon response to hypoglycemia in male diabetic ratsNinoschka C D'Souza, Nadia Aleali, Dorsa Shakeri, et al.
Frontiers in Pharmacology|March 21, 2024
Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetesNinoschka C D'Souza, Julian A Aiken, Emily G Hoffman, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Eye (London, England)|March 5, 2005
Deep sclerectomy augmented with mitomycin CN Anand, C Atherley
Eye (London, England)|September 25, 2004
Influence of ethnic origin on the incidence of keratoconus and associated atopic disease in Asian and white patientsI Cozma, C Atherley, N J James
Diabetes, Obesity & Metabolism|June 18, 2026
One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin-Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin-Requiring Type 2 DiabetesNinoschka C D'Souza, Emily G Hoffman, Sara C Atherley, et al.
Endocrinology|January 8, 2026
Prolonged somatostatin receptor 2 antagonism enhances glucagon response to hypoglycemia in male diabetic ratsNinoschka C D'Souza, Nadia Aleali, Dorsa Shakeri, et al.
Frontiers in Pharmacology|March 21, 2024
Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetesNinoschka C D'Souza, Julian A Aiken, Emily G Hoffman, et al.
Pageof 1